SEOUL -- Samsung Biologics closed $1.5 billion worth of orders in the past three months, as the world's leading contract biopharmaceutical manufacturer topped its sales for all of 2019 by 150% due to the coronavirus pandemic.
The South Korean company most recently signed a $314 million deal with an undisclosed European client.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)